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Abstract
Aims/hypothesis It is important to differentiate the two major phenotypes of adult-onset diabetes, autoimmune type 1 diabetes
and non-autoimmune type 2 diabetes, especially as type 1 diabetes presents in adulthood. SerumGAD65 autoantibodies (GADA)
are the most sensitive biomarker for adult-onset autoimmune type 1 diabetes, but the clinical value of GADA by current standard
radiobinding assays (RBA) remains questionable. The present study focused on the clinical utility of GADA differentiated by a
new electrochemiluminescence (ECL) assay in patients with adult-onset diabetes.
Methods Two cohorts were analysed including 771 diabetic participants, 30–70 years old, from the Action LADA study (n =
6156), and 2063 diabetic participants, 20–45 years old, from the Diabetes in Young Adults (DiYA) study. Clinical characteristics
of participants, including requirement of early insulin treatment, BMI and development of multiple islet autoantibodies, were
analysed according to the status of RBA-GADA and ECL-GADA, respectively, and compared between these two assays.
Results GADAwas the most prevalent and predominant autoantibody, >90% in both cohorts. GADA positivity by either RBA or
ECL assay significantly discriminated clinical type 1 from type 2 diabetes. However, in both cohorts, participants with
ECL-GADA positivity were more likely to require early insulin treatment, have multiple islet autoantibodies, and be less
overweight (for all p < 0.0001). However, clinical phenotype, age at diagnosis and BMI independently improved positive
predictive value (PPV) for the requirement of insulin treatment, even augmenting ECL-GADA. Participants with GADA
detectable by RBA, but not confirmed by ECL, had a phenotype more similar to type 2 diabetes. These RBA-GADA positive
individuals had lower affinity GADA compared with participants in which GADA was confirmed by ECL assay.
Conclusions/interpretation Detection of GADA by ECL assay, given technical advantages over RBA-GADA, identified
adult-onset diabetes patients at higher risk of requiring early insulin treatment, as did clinical phenotype, together allowing for
more accurate clinical diagnosis and management.
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IASP Islet autoantibody standardization program
LADA Latent autoimmune diabetes in adults
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ZnT8A Zinc transporter-8 autoantibodies
Introduction
Type 1 diabetes has been recently shown in epidemiological
studies to be predominantly a disease of adult onset [1–3].
Adult-onset type 1 diabetes is more heterogeneous than
childhood-onset type 1 diabetes; the majority of adults do not
require insulin treatment initially and have been arbitrarily
defined as having latent autoimmune diabetes in adults
(LADA) when off insulin treatment at least 6 months
post-diagnosis [4]. Distinguishing adult-onset type 1 diabetes
from type 2 diabetes is clinically important and commonly
employs the GAD65 autoantibody (GADA) assay [5]. Since
GADA is the dominant, often the only, diabetes-associated
autoantibody in adult-onset diabetes, it is possible that some
GADA positive participants have either biologically false posi-
tive GADA or GADA of limited clinical utility. Following
extensive validation, our recently developed electrochemilumi-
nescence (ECL) assay for GADA was more predictive of
progression to type 1 diabetes than current radiobinding assays
(RBA) in several major clinical trials [6, 7]. ECL assays
discriminate individuals with high affinity GADA at high
disease-risk from those identified by RBA with low affinity
GADA at low disease-risk. The present study aims to evaluate,
for the first time, GADA by ECL assay, compared with the
standard RBA, in individuals with adult-onset diabetes. We
hypothesised that identification of GADA using the ECL assay,
compared with the RBA, would have greater clinical utility in
screening adult-onset autoimmune diabetes by allowing for
more accurate clinical diagnosis to the benefit of clinical care.
Methods
Participants and samples Serum samples were obtained from
two large clinical studies, the Action LADA study in the UK
and the Diabetes in Young Adults (DiYA) study in the USA.
The Action LADA study is a cross-sectional study of adult
participants aged 30 to 70 years, with recent-onset diabetes
diagnosed within 5 years (originally n = 6156) (www.
actionlada.org) [5]. For the current study, 771 participants
with sufficient available sera were selected, including adult-
onset diabetes patients positive for RBA-GADA (n = 278,
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51.4% of the Action LADA cohort with RBA-GADA)with or
without insulinoma-associated antigen-2 autoantibodies (IA-
2A) or zinc transporter-8 autoantibodies (ZnT8A), and
patients negative for RBA-GADA (n = 493) (see Fig. 1).
The mean (SD) age was 51.5 (7.6) years, 54.0% were male,
69.5% were non-Hispanic White and mean duration of diabe-
tes was 2.4 (4.2) years with similar age (+/−5%) and diabetes
duration (+/−5%) between the two groups. DiYA is a prospec-
tive study to estimate the incidence of type 1 diabetes among
younger adults, aged 20 to 45 years, with recent-onset diabetes
[8]. Samples were collected among participants (mean [SD]
age 36.9 [6.1] years at diagnosis, 46% male, 24% non-
Hispanic White) at a median diabetes duration of 10 months.
All 2063 DiYA participants whose samples were measured
for islet autoantibodies (IAbs) by RBA were included in the
study, including individuals (n = 125) positive for RBA-
GADA with or without IA-2A or ZnT8A, and participants
(n = 1938) negative for RBA-GADA (Fig. 1). Clinical infor-
mation such as age, sex, ethnicity, BMI and insulin treatment
were collected from both studies. In the Action LADA cohort,
information for insulin treatment was available for 694 (90%)
of participants. In both studies, individuals on insulin treat-
ment at the latest sample and within 5 years of diagnosis were
considered to have ‘early insulin therapy’. Both studies were
approved by the responsible local ethics committees (institu-
tional review boards) and the study participants gave informed
consent.
RBA for GADA, IA-2A and ZnT8A RBA for all three autoanti-
bodies (GADA, IA-2A and ZnT8A) were performed at the
Blizard Institute, London, for the Action LADA study, and
at the Barbara Davis Center for Diabetes, University of
Colorado, USA, for the DiYA study. The methodologies have
been described previously [5, 6], and both laboratories used
full length GAD65 in their RBA. The GADA cut-offs were 68
(index) for the Blizard Institute laboratory and 20 (DK units)
for the Barbara Davis Center for Diabetes laboratory. GADA
achieved adjusted sensitivities of 64% at 95% specificity at the
Blizard Institute laboratory in the Islet Autoantibody
Standardization Program (IASP) workshop of 2012 when
the RBA were performed for the Action LADA study, and
sensitivity of 82% at 99% specificity at the laboratory in the
Barbara Davis Center for Diabetes (lab ID: 133) during the
IASP workshop of 2018 [9] when the RBA were performed
for the DiYA study.
ECL assay for GADA ECL-GADA assays were measured at the













































Fig. 1 Participants studied from
the Action LADA and DiYA
studies
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described [6]. In brief, serum samples were mixed with both
sulfo-tag- and biotin-labelled GAD65 (full length) antigen
proteins for overnight incubation at 4°C. The antigen–
antibody complexes labelled with biotin were captured by a
streptavidin-coated plate, and the sulfo-tag labelled complexes
gave the signals with ECL. The results were expressed as an
index against internal standard GAD65 positive controls. The
ECL assay cut-off index of 0.023 for GADA was set at the
99th percentile over 100 healthy controls, and the ECL
inter-assay CV was 8.8% (n = 10) for GADA. In the 2018
IASP Workshop [9], sensitivity for ECL-GADA was 82%
and specificity was 99%.
GADA affinity assay The GADA affinity assay was carried out
as previously described [6], and the native GAD65 protein
(Diamyd, Pi t tsburgh, PA, USA) was used in an
RBA-GADA competitive assay. For the present study, 43
samples in total were analysed, including 17 samples from
Action LADA (9GADApositive in both RBA and ECL assay
formats, and 8 GADA positive in RBA alone) and 26 samples
from DiYA (18 GADA positive in both RBA and ECL assay
formats, and 8 GADA positive in RBA alone). Two concen-
trations of unlabelled GAD65 protein (4.6 × 10−10 mol/l and
4.6 × 10−9 mol/l) were used for the competition assay.
Inhibitions for 50% of signals at the concentrations of
unlabelled GADA were compared between antibodies.
Statistical analysis All statistical analyses were performed
using GraphPad Prism v9.1.0 Software (https://www.
graphpad.com/scientific-software/prism/) and SAS v9.4 (SAS
Institute, Cary, NC, USA; https://support.sas.com/downloads/
package.htm?pid=2490). Continuous variables are reported as
mean or median and categorical variables are reported as the
number and percentage of participants with the characteristic of
interest and ORs (95% CI). Pearson’s correlation analysis was
performed to assess the strength of correlation between levels of
GADA in the two assays. To compare the levels of BMI across
the four diabetes-associated autoantibody groups, ANOVA
was used. Logistic regression analyses were used to test for
difference in per cent of requirement for insulin treatment and
per cent of multiple IAbs across the four groups. Firth’s
penalised likelihood approach was used to minimise the analyt-
ical bias caused by small samples, rare events and incomplete
separation. Sensitivity and positive predictive value (PPV) for
the prediction of early insulin use were calculated for various
cut-offs. For all tests, p values <0.05 were considered signifi-
cant with a two-tailed test.
Results
In adult-onset autoimmune diabetes GADA is dominant Two
distinct cohorts covering a wide age range of recently
diagnosed adult-onset diabetes patients (Action LADA and
DiYA) were studied using two different RBA-GADA assays,
as well as assays for IA-2A or ZnT8A, in their respective
centralised laboratories, while the same ECL- GADA assay
was used for both cohorts in one centralised laboratory.
Overall, IAb positivity was 9.7% (598/6156) in the Action
LADA study and 6.6% (136/2063) in the DiYA study.
RBA-GADA was the most prevalent autoantibody and
predominated, 90.5% (541/598) in the Action LADA study
and 91.9% (125/136) in the DiYA study, respectively, while
other IAbs (IA-2A or ZnT8A) were detected in only a small
fraction. In the total unselected Action LADA cohort (n =
6156), only 0.9% (57 of 6156) had IA-2A or ZnT8A alone
[5]. In the DiYA cohort (n = 2063), only 0.5% (11/2063) had
IA-2A or ZnT8 alone.
Unlike childhood-onset diabetes, the majority of
adult-onset diabetes patients positive for IAbs in these studies
were single positive for GADA without other IAbs (78.4%
[218/278] of the Action LADA participants studied had single
GADA+ and 66.4% [83/125] of the DiYA study participants
had single GADA+). The overall IAb positivity, including
GADA, IA-2A and ZnT8A is summarised in Fig. 2 for both
the Action LADA (Fig. 2a) and the DiYA studies (Fig. 2b).
Detection of GADA by either RBA or ECL assay has significant
clinical utility to differentiate type 1 diabetes from type 2
diabetes for adult-onset diabetes Participants who were
GADA positive in both assays, compared with individuals
who were negative for GADA with both assays (presumptive
type 2 diabetes, n = 482 in the Action LADA study and n =
1921 in the DiYA study), were: (1) leaner (p < 0.0001 and also
for each assay considered separately); (2) more frequently
positive for other IAbs i.e. IA-2A and/or ZnT8A (p < 0.0001
and also for each assay considered separately); and (3) more
often required early insulin treatment (p < 0.0001 and also for
each assay considered separately). In the Action LADA study,
the risk of insulin therapy was significantly higher in partici-
pants who were GADA positive with both assays (OR 10.87
[95%CI 6.42, 18.39]; p < 0.0001), comparedwith participants
who were negative for GADA with both assays, but also with
either RBA alone (OR 6.51 [95% CI 4.02, 10.54]; p < 0.0001;
PPV 28.6%) or ECL assay alone (OR 8.78 [95% CI 5.49,
14.03]; p < 0.0001; PPV 37.4%). The DiYA study also found
the risk of requiring insulin therapy was significantly higher in
individuals with both RBA-GADA and ECL-GADA positiv-
ity (OR 3.75 [95% CI 2.44, 5.75]; p < 0.0001), compared with
participants negative for GADA with both assays, and also
higher in those with either RBA-GADA alone (OR 2.61
[95% CI 1.77, 3.85]; p < 0.0001; PPV 34.4%) or
ECL-GADA alone (OR 3.45 [95% CI 2.27, 5.26];
p < 0.0001; PPV 40.8%). Levels of GADA from RBA and
ECL assays in both the Action LADA (n = 771) and DiYA
(n = 2063) studies, are plotted in Fig. 3a and b, respectively.
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Levels in individuals whowere GADA positive in both assays
were correlated (for Action LADA r = 0.3208, p < 0.0001, and
for DiYA r = 0.5771, p < 0.0001). Interestingly, in both
cohorts, the risk of requiring early insulin therapy was not
associated with levels of either RBA-GADA or ECL-GADA.
RBA detectedmore GADA but was less specific than ECL assay
In both studies, more participants were identified as
RBA-GADA positive than ECL-GADA positive. In the pres-
ent Action LADA cohort (n = 771), 278 individuals were
RBA-GADA positive by selection. In this cohort, 188/771
(24.4%) were posit ive for both RBA-GADA and
ECL-GADA, 90 (11.7%) had RBA-GADA alone, while only
11 (1.4%) had ECL-GADA alone. In the DiYA cohort, 93/
2063 (4.5%) had both RBA-GADA and ECL-GADA, 32
(1.6%) were positive for RBA-GADA alone, while only 5
(0.2%) had ECL-GADA alone. As such, between 26%
(DiYA study) and 32% (Action LADA) of GADA detected
by RBA was not detected by ECL. In both studies,
ECL-GADA positivity was particularly reduced in individuals
with single IAb positivity or RBA-GADA positivity alone. In
the Action LADA cohort, ECL-GADA was only found in
62% of participants (136/218) with RBA-GADA alone,
compared with participants with more than one autoantibody,
i.e. GADA plus IA-2A and/or ZnT8A (52/60 [87%], p =
0.0003), as shown in Fig. 3a. Similarly in the DiYA study,
ECL-GADA positivity was only found in 61% of individuals
with RBA-GADA alone (51/83) and in 100% of participants
with RBA-GADA and IA-2A and/or ZnT8A (42/42,
























































Fig. 3 Comparison of GADA levels between RBA and ECL assay in the
(a) Action LADA study (n = 771) and (b) DiYA study (n = 2063). The
solid dots represent individuals positive for IA-2A and/or ZnT8A and the
open dots negative for IA-2A and ZnT8A. The dotted lines indicate assay
cut-offs. RBA-GADA was tested at the Blizard Institute laboratory,
London, for the Action LADA study, with a cut-off value of 68 (index),
and at the Barbara Davis Center for Diabetes laboratory, USA, for the
DiYA study, with a cut-off value of 20 (DK units). The ECL-GADA
assay was performed at the Barbara Davis Center for Diabetes for both
Action LADA and DiYA studies, with a cut-off value of 0.023 (index)
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defined by RBA-GADA positivity, but not confirmed by the
ECL-GADA assay, had a phenotype more similar to type 2
diabetes from both the Action LADA and the DiYA cohorts as
shown in Figs 4 and 5. They were more obese (mean BMI
30.7 kg/m2 vs 23.3 kg/m2 in the Action LADA cohort,
38.8 kg/m2 vs 29.5 kg/m2 in the DiYA cohort, both
p < 0.0001), less likely to have multiple IAbs (8/90 [8.9%]
vs 52/188 [27.7%], p = 0.0003) and 0/32 vs 42/93 [45.2%],
p < 0.0001, respectively), and less often required early insulin
treatment(10/81 [12.3%] vs 61/162 [37.7%] and 3/32 [9.4%]
vs 40/93 [43.0%], respectively, both p < 0.0001).
Individuals who were RBA-GADA positive not confirmed
by ECL assay, compared with individuals GADA negative in
both assays, still showed increased requirement for early insu-
lin treatment in the Action LADA cohort (Fig. 4b; 12.3% vs
5.2%), while it was the opposite in the DiYA cohort (Fig. 5b;
9.4% vs 16.8%). Levels of RBA-GADA in both cohorts were
significantly lower in those who were ECL-GADA negative
(p = 0.0002 for Action LADA and p < 0.0001 for DiYA), but
absolute levels were not discriminatory (Fig. 3). Interestingly,
in both studies, other IAbs (IA-2A and/or ZnT8A) did not
increase the risk of requiring early insulin treatment in partic-
ipants who were ECL-GADA positive. By contrast, in young
adult-onset diabetes (DiYA), in individuals who were
RBA-GADA positive, the addition of other IAbs was associ-
ated with increased frequency of early insulin treatment (21/
42 [50%] vs 22/83 [26.5%], p = 0.01), but not in the older
adult-onset diabetes (Action LADA).
RBA-GADA not confirmed by ECL assay were of low affinityTo
confirm our previous finding that GADA affinity is higher when
positive in the ECL-GADA assay as compared with
RBA-GADA alone [6, 7], GADA affinity was analysed by
competitive RBA in a total of 43 samples, including 17 samples
from the Action LADA study (nine GADA positive in both
RBA and ECL and eight only positive for RBA-GADA) and
26 samples from the DiYA study (18 GADA positive in both
RBA and ECL, and eight samples only positive for
RBA-GADA). The levels of RBA-GADA were selected to be
similar between the two subgroups for affinity comparison. At
the concentrations of 4.6 × 10−10 mol/l and 4.6 × 10−9 mol/l of
unlabelled GAD65, GADA confirmed by ECL assay were
absorbed by a mean of 76% and 94%, respectively, while
GADA not confirmed by ECL assay were absorbed by a mean
of 28% and 54%, respectively. Results (Fig. 6) confirmed that
samples which were positive for RBA-GADA alone required a
higher concentration of native GAD65 protein for 50% binding
inhibition.
Clinical phenotype augments GADA to predict early insulin
use Patient demographics impacted the risk of requiring early
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Fig. 4 Clinical features were compared in four groups of participants with
adult-onset diabetes from the Action LADA study: RBA-GADA+
confirmed by ECL assay, RBA-GADA+ not confirmed by ECL assay,
ECL-GADA+ only, and GADA– in both RBA and ECL assay. (a) BMI
values; (b) per cent of participants requiring early insulin treatment; (c)
per cent of participants positive for multiple IAbs. *p < 0.05,
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Fig. 5 Clinical features were compared in four groups of participants with
adult-onset diabetes from the DiYA study: RBA-GADA+ confirmed by
ECL assay, RBA-GADA+ not confirmed by ECL assay, ECL-GADA+
only, and GADA– by both RBA and ECL assay. (a) BMI values; (b) per
cent of participants requiring early insulin treatment; (c) per cent of partic-
ipants positive for multiple IAbs. *p < 0.05, ***p < 0.001 by ANOVA
test or logistic regression analyses
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earlier age at diagnosis (DiYA compared with Action LADA)
and lower BMI (<25 kg/m2) were independently associated
with higher PPV and together augmented the PPV of both
RBA-GADA and ECL-GADA for early insulin treatment in
both cohorts. RBA-GADA positivity and BMI <25 kg/m2
together increased PPV from 28.1% to 42.3% in the Action
LADA cohort, and from 34.4% to 58.3% in the DiYA cohort.
ECL-GADA positivity and BMI <25 kg/m2 together
increased PPV from 37.4% to 45.7% in the Action LADA
cohort, and from 40.8% to 55.3% in the DiYA cohort.
ECL-GADA positivity and BMI <25 kg/m2 together had a
higher PPV in the DiYA cohort than the Action LADA cohort
(55.3% vs 45.7%) but at the cost of predictive sensitivity in the
DiYA cohort (sensitivity only 5.7%) (Table 1).
Discussion
This study demonstrated that GADA, whether detected by RBA
or ECL assays, recognised a clinical phenotype distinct from type
2 diabetes in adult-onset diabetes patients, in that individuals were
leaner, with a higher frequency of multiple autoantibodies and
earlier need for insulin therapy. This present investigation of
two independent studies of an older and younger adult cohort in
theUKandUSA, respectively, covered awide age range of adults
in two different populations. In both cohorts, GADA was shown
to be prevalent and dominant, the majority of individuals having
only single GADA positivity without other IAbs (78% in the
Action LADA study and 66% in theDiYA study). Of participants
withGADAalone byRBA, 62% in theActionLADAcohort and
61% in the DiYA cohort were confirmed positive using
ECL-GADA. In our previous studies of type 1 diabetes-risk
screening, we repeatedly found that when screening either indi-
viduals from the general population (with type 1
diabetes-associated HLA alleles) or their relatives, of those who
were RBA-GADA positive alone, 40% or fewer showed positiv-
ity confirmed by the ECL assay (data from three large clinical
trials; Diabetes Autoimmunity Study in the Young [DAISY] [6],
TrialNet [7] and The Environmental Determinants of Diabetes in
the Young [TEDDY; unpublished data]). In an ongoing large
screening study of unselected children from the general popula-
tion (Autoimmunity Screening for Kids [ASK]), of those children
with RBA-GADA positivity alone, only 20%were confirmed by
ECL assay (L. Yu, unpublished data). Samples which were
GADA positive by RBA alone, not confirmed by ECL assay,
had lower affinity in both our previous studies, as well as this
present study.
Higher affinity GADA predicts progression to type 1 diabetes
[6, 7, 10], and in LADA predicts requirement of early insulin
treatment [11]. We, and others, recently reported that
RBA-GADA to N-terminal GAD epitopes contribute to low
affinity positivity, while RBA-GADA assays using N-terminally
truncated GAD improves clinical phenotyping in both type 1
diabetes and adult-onset diabetes to a comparable degree [12,
13]. In the TrialNet study, participants who were GADA positive
by RBA, but not by ECL, did not show impaired glycaemia
during follow-up (median 4.7 years), while ECL-GADA positive
participants had comparable dysglycaemia to individuals with
multiple IAbs at high risk of type 1 diabetes [14]. Our results
likely reflect the known importance of enrichment by ascertain-
ment to enhance the clinical utility of an assay, thereby explaining

















Fig. 6 GADA affinity analysis. In total, 43 serum samples positive for
RBA-GADA, including 17 samples from the Action LADA study (blue;
nine confirmed by ECL assay and eight not confirmed by ECL assay) and
26 samples from the DiYA study (red; 18 confirmed by ECL assay and
eight not confirmed by ECL assay) were analysed using competitive
RBA and incubation with different concentrations of native GAD65
protein. GADA not confirmed by ECL assay (dotted line), comparedwith
GADA confirmed by ECL assay (solid line), required higher concentra-
tions of GAD65 protein for 50% maximal inhibition. Results were
expressed as per cent of signal not absorbed
Table 1 Clinical utility of GADA
(RBA and ECL) assays and demo-
graphics (BMI) for predicting early
insulin treatment in two cohorts
(Action LADA and DiYA). PPV
and sensitivity as a marker of early
insulin treatment. Whilst PPV with
ECL-GADA is higher than with
RBA-GADA it can be further
enhanced in both cohorts using low
BMI (<25 kg/m2)
舃Action LADA 舃DiYA
舃Characteristic 舃PPV 舃Sensitivity 舃PPV 舃Sensitivity
舃BMI <25 kg/m2, n (%) 舃55/166 (33.1) 舃55/94 (58.5) 舃39/127 (30.7) 舃39/368 (10.6)
舃RBA-GADA+, n (%) 舃70/249 (28.1) 舃70/96 (72.9) 舃43/125 (34.4) 舃43/368 (11.7)
舃ECL-GADA+, n (%) 舃64/171 (37.4) 舃64/96 (66.7) 舃40/98 (40.8) 舃40/ 368 (10.9)
舃RBA-GADA+ & BMI<25 kg/m2, n (%) 舃47/111 (42.3) 舃47/93 (50.5) 舃21/36 (58.3) 舃21/368 (5.7)
舃ECL-GADA+ & BMI<25 kg/m2, n (%) 舃43/94 (45.7) 舃43/93 (46.2) 舃21/38 (55.3) 舃21/368 (5.7)
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in individuals with RBA-GADA positivity alone, ranging from
20% (children in the general population), 40% (relatives of indi-
viduals with type 1 diabetes), compared here with 60% in
adult-onset diabetes patients. While higher affinity GADA
predicts progression to type 1 diabetes [6, 7, 10], and in both adult
cohorts reported here, an increased requirement for insulin treat-
ment [11], measurement of GADA affinity is time consuming
and expensive with limited clinical applicability. Large prospec-
tive studies could establish whether different assays, seeking
different epitope specificities or affinities, might benefit from clin-
ical and predictive utility without losing predictive sensitivity.
Importantly, our data indicated that clinical phenotype, namely
age at diagnosis and BMI, can also influence risk of progression
to early insulin treatment independently of immunotype.
Participants in the younger DiYA cohort consistently had higher
PPV for GADA alone or in association with low BMI than the
Action LADA cohort did, irrespective of the nature of the GADA
assay. For the younger DiYA cohort, a low BMI had poor sensi-
tivity as so few of them were lean. Nevertheless, our data implies
an important role for features other than immunotype in predicting
early insulin treatment, a novel observation that deserves further
exploration.
There are some limitations to this study. The samples analysed
from the initial Action LADA cohort are relatively few, albeit
randomly selected based on sample availability from an initial
cohort of over 6000 patients. Insulin therapy was started as a
clinical decision and not based on a universal algorithm. The data
are cross-sectional, though we predict that follow-up would likely
increase the clinical utility of ECL-GADA [13, 14].
Importantly, both assay formats, including here the ECL assay,
as well as epitope specificity with truncated GAD65 in RBAwill
likely be of practical clinical value in identifying autoantibodies
predictive of early insulin therapy. Both assay formats improved
the odds of requiring insulin therapy in the same LADA cohort as
compared with the standard RBA-GADA assay. The ECL assay
may be additionally valuable because it does not use radioactivity,
is approved to equip other IAb (insulin autoantibodies, IA-2A and
ZnT8A) assays with high affinity specificity with the same
format, and is capable of large throughput with low cost, espe-
ciallywith its unique advantage ofmultiplexing to combinemulti-
ple autoantibody assays in one singlewell [15]. Once these results
are confirmed, routine screening for GADA, such as the
ECL-GADA assay, added to demographic features, should be
explored further in patients with adult-onset diabetes for enhanced
clinical utility.
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